177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …

JR Strosberg, ME Caplin, PL Kunz… - The Lancet …, 2021 - thelancet.com
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …
被引用次数：257 相关文章
[PDF] ahpba.org

[PDF][PDF] ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall …

JR Strosberg, ME Caplin, PL Kunz, PB Ruszniewski… - Lancet Oncol, 2021 - ahpba.org
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with ¹⁷⁷Lu-Dotatate plus long-acting octreotide …

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …

JR Strosberg, ME Caplin, PL Kunz, PB Ruszniewski… - The Lancet …, 2021 - Elsevier
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …

JR Strosberg, ME Caplin, PL Kunz… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …

JR Strosberg, ME Caplin, PL Kunz… - The Lancet …, 2021 - europepmc.org
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …